|
1
|
Ferguson-Smith AC: Genetic imprinting:
silencing elements have their say. Curr Biol. 10:R872–R875.
2000.
|
|
2
|
Ohlsson R, Nystrom A, Pfeifer-Ohlsson S,
et al: IGF2 is parentally imprinted during human embryogenesis and
in the Beckwith-Wiedemann syndrome. Nat Genet. 4:94–97. 1993.
|
|
3
|
Rainier S, Johnson LA, Dobry CJ, et al:
Relaxation of imprinted genes in human cancer. Nature. 22:747–749.
1993.
|
|
4
|
Cui H, Horon IL, Ohlsson R, Hamilton SR
and Feinberg AP: Loss of imprinting in normal tissue of colorectal
cancer patients with microsatellite instability. Nat Med.
4:1276–1280. 1998.
|
|
5
|
Nakagawa H, Chadwick RB, Peltomaki P, et
al: Loss of imprinting of the insulin-like growth factor II gene
occurs by biallelic methylation in a core region of H19-associated
CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA.
98:591–596. 2001.
|
|
6
|
Takano Y, Shiota G and Kawasaki H:
Analysis of genomic imprinting of insulin-like growth factor 2 in
colorectal cancer. Oncology. 59:210–216. 2000.
|
|
7
|
Kohda M, Hoshiya H, Katoh M, et al:
Frequent loss of imprinting of IGF2 and MEST in lung
adenocarcinoma. Mol Carcinog. 31:184–191. 2001.
|
|
8
|
Xu W, Fan H, He X, Zhang J and Xie W: LOI
of IGF2 is associated with esophageal cancer and linked to
methylation status of IGF2 DMR. J Exp Clin Cancer Res. 25:543–547.
2006.
|
|
9
|
Byun HM, Wong HL, Birnstein EA, et al:
Examination of IGF2 and H19 loss of imprinting in bladder cancer.
Cancer Res. 67:10753–10758. 2007.
|
|
10
|
Zuo QS, Yan R, Feng DX, et al: Loss of
imprinting and abnormal expression of the insulin-like growth
factor 2 gene in gastric cancer. Mol Carcinog. 50:390–396.
2011.
|
|
11
|
Cheng L, Alexander RE, Maclennan GT, et
al: Molecular pathology of lung cancer: key to personalized
medicine. Mod Pathol. 25:347–369. 2012.
|
|
12
|
Trajkovic-Arsic M, Kalideris E and Siveke
JT: The role of insulin and IGF system in pancreatic cancer. J Mol
Endocrinol. 50:R67–R74. 2013.
|
|
13
|
Vincent EE, Elder DJ, Curwen J, et al:
Targeting non-small cell lung cancer cells by dual inhibition of
the insulin receptor and the insulin-like growth factor-1 receptor.
PLoS One. 8:e669632013.
|
|
14
|
Nie ZL, Pan YQ, He BS, et al: Gene therapy
for colorectal cancer by an oncolytic adenovirus that targets loss
of the insulin-like growth factor 2 imprinting system. Mol Cancer.
11:862012.
|
|
15
|
Uejima H, Lee MP, Cui H and Feinberg AP:
Hot-stop PCR: a simple and general assay for linear quantitation of
allele ratios. Nat Genet. 25:375–376. 2000.
|
|
16
|
Maenaka S, Hikichi T, Imai MA, Minamoto T
and Kawahara E: Loss of imprinting in IGF2 in colorectal carcinoma
assessed by microdissection. Oncol Rep. 15:791–795. 2006.
|
|
17
|
Kaneda A, Wang CJ, Cheong R, et al:
Enhanced sensitivity to IGF-II signaling links loss of imprinting
of IGF2 to increased cell proliferation and tumor risk. Proc Natl
Acad Sci USA. 104:20926–20931. 2007.
|
|
18
|
Liu P, Morrison C, Wang L, et al:
Identification of somatic mutations in non-small cell lung
carcinomas using whole-exome sequencing. Carcinogenesis.
33:1270–1276. 2012.
|
|
19
|
Suzuki A, Mimaki S, Yamane Y, et al:
Identification and characterization of cancer mutations in Japanese
lung adenocarcinoma without sequencing of normal tissue
counterparts. PLoS One. 8:e734842013.
|
|
20
|
Douillard JY, Shepherd FA, Hirsh V, et al:
Molecular predictors of outcome with gefitinib and docetaxel in
previously treated non-small-cell lung cancer: data from the
randomized phase III INTEREST trial. J Clin Oncol. 28:744–752.
2010.
|
